A phase 1, open-label, dose-escalation, multiple dose study of the safety, tolerability, and immune response of CRS-207 in adult subjects with selected advanced solid tumors who have failed or who are not candidates for standard treatment

Trial Profile

A phase 1, open-label, dose-escalation, multiple dose study of the safety, tolerability, and immune response of CRS-207 in adult subjects with selected advanced solid tumors who have failed or who are not candidates for standard treatment

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2012

At a glance

  • Drugs CRS 207 (Primary)
  • Indications Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Feb 2012 Results were published in Clinical Cancer Research.
    • 18 Apr 2011 Top-line results reported in a Aduro BioTech media release.
    • 15 Jul 2010 Tolerability and preliminary analysis of long-term survival data has been reported in a Aduro Biotech media release. Further results are expected later in 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top